Related Experiment Video
Updated: Sep 19, 2025
05:59
Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
Published on: October 20, 2023
2.6K
Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice
Craig Chepke1,2, Ruth M Benca3, Andrew J Cutler4
1Excel Psychiatric Associates, Huntersville, North Carolina.
The Journal of Clinical Psychiatry
|June 9, 2025
Summary
Idiopathic hypersomnia, a sleep disorder, is often seen in psychiatric patients due to high comorbidity. Early recognition and management can improve patient outcomes.
Area of Science:
- Neurology
- Psychiatry
- Sleep Medicine
Background:
- Idiopathic hypersomnia is a central sleep disorder characterized by excessive daytime sleepiness (EDS).
- It affects up to 1.5% of the population and is frequently comorbid with psychiatric conditions.
- Symptoms include sleep inertia, long sleep times, cognitive issues, and autonomic dysfunction.
Purpose of the Study:
- To review the relationship between idiopathic hypersomnia and psychiatric disorders.
- To outline considerations for recognizing and managing EDS in psychiatric patients.
- To highlight diagnostic and treatment challenges.
Main Methods:
- A comprehensive literature search was conducted using terms like "idiopathic hypersomnia" and "psychiatric" in PubMed and Embase.
- English-language human studies published up to July 2024 were included.
- Articles were screened for relevance to idiopathic hypersomnia and psychiatric populations, with reference list searches.
Main Results:
- 119 articles were included in the review.
- Idiopathic hypersomnia presents with EDS, sleep inertia, and cognitive complaints, affecting up to 1.5% of the population.
- High rates of psychiatric comorbidities, such as mood disorders and ADHD, are observed in patients with idiopathic hypersomnia.
Conclusions:
- Psychiatric clinicians are likely to encounter idiopathic hypersomnia more frequently than its general prevalence suggests due to comorbidity.
- Recognizing and managing idiopathic hypersomnia in psychiatric patients can enhance treatment effectiveness.
- Careful assessment is needed due to potential interactions between psychiatric medications and idiopathic hypersomnia treatments.
Related Concept Videos
01:19Management of Insomnia
328
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
328
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
249
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
249
01:07Narcolepsy
205
Narcolepsy is a chronic sleep disorder characterized by pervasive, uncontrolled sleepiness and other sleep disturbances. One of its hallmark symptoms is an abrupt transition to REM sleep upon falling asleep, which causes symptoms typically associated with this phase to occur unexpectedly during wakefulness. These include the following symptoms, which typically last from a minute or two to half an hour.
205
01:14CNS Depressants: Barbiturates and Benzodiazepines
484
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
484
01:27Insomnia
133
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress.
Multiple factors contribute...
Multiple factors contribute...
133
01:23Sedatives and Hypnotics: Overview
697
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
697